Pilot Study: Effects of Nimodipine on Alcohol Drinking
A legfontosabb adatok
- Ki végzi
- Yale University
- Hol
- New Haven (Egyesült Államok)A helyszín megnézése
- Azonosító
- Állapot
- Toborzás még nem indult
- Fázis
- 2. fázis
- Résztvevők
- 5 fő, tervezett
- Kezdés
- 2026. szept. 1.
- Várható befejezés
- 2032. jún. 30.
- A vizsgálat típusa
- Beavatkozással járó
- A vizsgált kezelések
- Nimodipine
- A regiszteradat frissítve
- 2026. március 17.
Ki vehet részt
- Életkor
- 21 év – 50 év
- Nem
- Nők és férfiak
- Egészséges önkéntesek
- Nem vehetnek részt
A regiszter feltételei, szó szerint
Mind a 23 feltétel megnézéseKevesebb
Ki vehet részt
- Ages 21-50 (The lower limit is to avoid offering alcohol to individuals below the drinking age of 21. The upper age is determined by experience recruiting for our prior studies)
- Ability to read English at 6th grade level or higher
- Meet DSM-V criteria for at least moderate AUD
- Average weekly alcohol consumption of 30-70 standard drinks for men and 20-65 drinks for women. The lower limits are consistent with the lower sex-specific cut-offs defining high-risk drinking based on World Health Organization Risk Levels (WHO, 2000); the upper limits are designed to avoid recruiting participants whose drinking is likely to exceed the number of drinks available in the alcohol drinking paradigm (ADP)
Ki nem vehet részt
- Positive urine drug screens at more than 1 baseline appointment for opiates, cocaine, benzodiazepines, and barbiturates
- Regular use of psychoactive drugs, except for individuals on a stable dose of an antidepressant for at least 2 months
- Participants who refuse to use a reliable method of birth control from the time of first medication administration to 7 days after. These include oral contraceptives, contraceptive sponge, patch, double barrier (diaphragm/spermicidal or condom/spermicidal), intrauterine contraceptive system, etonogestrel implant, medroxyprogesterone acetate contraceptive injection, complete abstinence from sexual intercourse, hormonal vaginal contraceptive ring, surgical sterilization, or true abstinence
- Subjects who have taken any investigational drug within 4 weeks of the anticipated date of the first study dose
- Individuals who report heavy drinking days in the 2 days prior to their intake appointment but have a negative ethyl glucuronide (EtG) test to rule out subjects who are misrepresenting their drinking history
- Meet current DSM-V criteria for substance use disorder, except for tobacco use disorder or mild cannabis use disorder
- Psychotic or other severe psychiatric disorders as determined by clinical evaluation
- Medical conditions that would contraindicate the consumption of alcohol or use of nimodipine including untreated or not adequately controlled hypertension or hypotension. Blood pressure at or below 100/65 will be exclusionary
- Heart rate of less than 50 bpm
- Neurological trauma or disease, delirium, or hallucinations, or clinically significant or unstable medical conditions, including uncontrolled hypertension or diabetes, or significant cardiac, pulmonary, renal, hepatic, endocrine, or other systemic diseases, which in the opinion of the study physician and PI, may put the patient at risk because of participation in the study
- Clinical Institute Withdrawal Assessment for Alcohol-Revised (CIWA-Ar) scores of 8 or greater or a history of significant repeated alcohol withdrawals to reduce the likelihood of withdrawal symptomatology if subjects reduce their drinking
- Heart rate of less than 50 bpm
- Clinically significant abnormalities in screening laboratories, including aspartate aminotransferase (AST) >3 times upper limit of normal (ULN); alanine aminotransferase (ALT) > 3 times ULN; total bilirubin >1.5 times ULN; serum creatinine >2.0 times ULN
- Concurrent use of the following medications: CYP3A4 inhibitors and inducers, other calcium channel blockers, or other blood pressure lowering medications
- Individuals who are seeking alcohol treatment or have been in alcohol treatment within the past 6 months
- Women who are pregnant or nursing
- Subjects who report disliking spirits will be excluded because hard liquor will be provided during the ADP
- Subjects who have donated blood within the past 6 weeks
- Subjects with a history or presence of cirrhosis
A fő feltételek kérdésként
Magadról válaszolj. Ez nem döntés: hogy részt vehetsz-e, azt csak a vizsgálat csapata mondhatja meg.
- 21 és 50 év között vagy?
Helyszínek itt: Egyesült Államok
- Yale University School of Medicine, Connecticut Mental Health CenterNew Haven, Egyesült ÁllamokContact: Thomas LissToborzás még nem indult
A vizsgálatról
Mit akar kideríteni a vizsgálat
This is an open label trial aiming to recruit 5 non-treatment seeking adults with Alcohol Use Disorder. All will participate in an alcohol drinking paradigm (ADP) lab session at the Hospital Research Unit (HRU) at Yale-New Haven Hospital (YNHH). Participants will stay overnight and receive nimodipine 90 mg/dose every six hours during an 18-hour period prior to the ADP to allow for the limited central nervous system bioavailability of this drug. Electroencephalogram (EEG) data will be collected before the first dose and after the last dose of nimodipine. Adverse events will be closely monitored during this period. During the ADP session participants will receive a priming dose of alcohol followed by a one-hour monitoring period. This will be followed by three one-hour self-administration periods; during each hour, participants will be able to choose between drinking up to four drinks or receive the monetary equivalents of these drinks (total of 12 drinks over three hours).
A vizsgálat csoportja
- NimodipineA vizsgált kezelés
All participants will be assigned to this arm and will receive study drug (nimodipine), open label.
Kérdések a vizsgálat csapatának
- Milyen gyakran kell bejárnom, és egy-egy alkalom mennyi ideig tart?
- Megtérítik az utazási költséget?
- Megtarthatom a saját orvosomat?
- Mi történik, ha ki akarok lépni?
Contact the study team: see the registry record → Contacts and Locations
Oldal nyomtatása az orvosomnakAdatok és források
- Regiszteradat
- Szerepel a ClinicalTrials.gov-on.
- Hivatalos cím
- A Pilot Study on the Effects of Nimodipine on Alcohol Drinking Among Adults Who Are Heavy Alcohol Drinkers
- Kérdések a feltételekről
- Forrás: NCT06900998: ki vehet részt
- A regiszteradat frissítve
- 2026. március 17.